This excerpt taken from the NVO 6-K filed Oct 30, 2009.
Capital expenditure
is now expected to be around DKK 2.5 billion in 2009,
primarily reflecting timing of activities in relation to the new insulin formulation
and filling plant in China. Expectations for
Bet you've never seen portfolio analytics like these.